Durvalumab vs Upadacitinib

Durvalumab vs Upadacitinib: Overview

This comparison examines the pharmacological differences between Durvalumab and Upadacitinib.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Upadacitinib: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Upadacitinib — 9-14 hours.

Chemical Properties

Molecular Formula: Upadacitinib — C17H19F3N6O.

Molecular Weight: Upadacitinib — 380.3700 g/mol.

Type: Durvalumab — Antibody; Upadacitinib — Small molecule.